Rapid-onset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 219-233

  Andersson, C ^a   Wenander, C S ^a   Usher, P A ^a   Hebsgaard, J B ^a   Sondergaard, B C ^a   Rono B ^a   Mackay, C ^b   Friedrichsen, B ^a   Chang, C ^a   Tang, R ^a   Hornum, L ^a  

^a NOVO NORDISK A S   (Denmark)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Anti C5aR; Arthritis; Macrophages; Neutrophils

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR IGG2A 1 ANTIBODY; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; TNP IGG2A 1 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; INFANT; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTI-C5AR; ARTHRITIS; MACROPHAGES; NEUTROPHILS;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MICE; MICE, INBRED DBA; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; RHEUMATIC FEVER;

EID: 84904243241     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12338     Document Type: Article

References (47)

1. McInnes I, Schette G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
2. Bossaller L, Rothe A. Monoclonal antibody treatments for rheumatoid arthritis. Expert Opin Biol Ther 2013; 13:1275-1282.
3. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011; 13:S5.
4. Makinde MA, Senaldi G, Jawad AS, Berry H, Vergani D. Reflections on disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 1989; 48:302-306.
5. Sturfeld G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol 2012; 8:458-468.
6. Klareskog L, Malmström V, Lundberg K, Padyukov L, Alfredsson L. Smoking, citrullination and genetic viability in the immunepathogenesis of rheumatoid arthritis. Semin Immunol 2011; 23:92-98.
7. Guo RF. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23:821-852.
8. DiScipio R. C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int Immunopharmacol 2006; 6:1109-1118.
9. Zhou W. The new face of anaphylatoxins in immune regulation. Immunobiology 2012; 217:225-234.
10. Gonzales JM. Complement activation triggers metalloproteinases release inducing cervical remodelling and preterm birth in mice. Am J Pathol 2011; 179:838-849.
11. Cavaillon JM, Fitting C, Haefner-Cavillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopollysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20:252-257.
12. Gross V, Andus T. Human recombinant C5a enhances lipopollysaccharide-induced synthesis of interleukin 6 by human monocytes. Eur J Clin Invest 1992; 221:271-276.
13. Seow V, Lim J, Lyer A etal. Inflammatory responses induced by lipopolysacchraide are amplified in primary human monocytes but are suppressed by macrophages by complement protein C5a. J Immunol 2013; 191:4308-4316.
14. Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990; 49:747-752.
15. Hogasen K, Mollnes TE, Harboe M, Götze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995; 22:24-28.
16. Song JJ. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121:3517-3527.
17. Neumann E. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 2002; 46:934-945.
18. Kiener HP, Baghestanian M, Dominkus M etal. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:233-245.
19. Tu Z, Bu H, Dennis JE, Lin F. Efficient osteoclast differentiation requires local complement activation. Blood 2010; 116:4456-4463.
20. Ignatius A, Schoengraf P, Kreja L etal. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1b. J Cell Biochem 2010; 112:2594-2605.
21. Grant EP, Picarella D, Burwell T etal. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 2002; 196:1461-1471.
22. Wang Y, Rollins SA, Madin JA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92:8955-8959.
23. Nandakumar KS, Jansson A, Xu B etal. A recombinant vaccine effictively induces C5a-specific neutralizing antibodies and prevents arthritis. PLOS ONE 2010; 5:e13511.
24. Banda NK, Hyatt S, Antonioli AH etal. Role of C3a recpetors, C5a receptors, and complement protein C6 deficiency in collagen induced antibody arthritis in mice. J Immunol 2012; 188:1469-1478.
25. Lee H, Zahra D, Vogelzang A etal. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol 2006; 24:1279-1284.
26. Woodruff TM, Strachan AJ, Dryburgh N etal. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002; 46:2476-2485.
27. Hashimoto M, Hirota K, Yoshitomi H etal. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med 2010; 207:1135-1143.
28. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003; 25:3-18.
29. Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007; 7:65-70.
30. Bevaart L, Vervoordeldonk MJ, Tak PP. Evaluation of therapeutic targets in animal models: how does this relate to rheumatoid arthritis. Arthritis Rheum 2010; 62:2192-2205.
31. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 2007; 179:1369-1380.
32. Suzuki M, Uetsuka K, Suzuki M, Shinozuka J, Nakayama H, Doi K. Immunohistochemical study on type II collagen-induced arthritis in DBA/1J mice. Exp Anim 1997; 46:259-267.
33. Shushakova N, Skokowa J, Schulman J etal. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002; 110:1823-1830.
34. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004; 50:985-998.
35. Lee H, Whitfeld PL, Mackay CR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol 2008; 86:153-160.
36. Santos LL, Fan H, Pam Hall P etal. Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum 2011; 63:960-970.
37. Ogata H, Takeya M, Yoshimura T, Takagi K, Takahashi K. The role of monocyte chemoattractant parotein-1 (MCP-1) in the pathogenesis of collagen induced arthritis. J Pathol 1997; 182:106-114.
38. Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol 2006; 33:1523-1529.
39. Nimmerjahn F. Activating and inhibitory FcgRs in autoimmune disorders. Springer Semin Immunol 2006; 28:305-319.
40. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13:159-175.
41. Foreman KE, Glovsky MM, Warner RL, Horvath SJ, Ward PA. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 1996; 20:1-9.
42. Koelink PJ, Overbeek SA, Braber S etal. Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 2012; 133:1-18.
43. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation - therapeutic opportunities and pharmacological challenges. Pharmacol Rev 2013; 65:47-89.
44. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 in human rheumatoid arthritis. Arthritis Rheum 1996; 39:1576-1587.
45. Hausman M, Potter C, Marshall N etal. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 2012; 14:R30.
46. Tchetverikov I, Ronday HK, Van El B etal. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63:881-883.
47. Yoshihara Y, Nakamura H, Obata K etal. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59:455-461.